Kathleen thl*:
I have been asked to talk today about the Food and
Drug Administration (FDA) and the issue of women
in clinical drug studies, including the impact of having
women in those studies. I will give you a perspective
irom the FDA and go over some of the regulations
that govern women in clinical studies. I will end with
some food for thought as to what it might mean, 10m
a broader perspective, to include women in clinical
trials.
First of all I just want to tell you what the FDA is. I
give numerous presentations at medical organizations
where there are a lot of physicians, pharmacists,
nurses, et cetera, many of whom think they know what
the FDA is. Yet I often find that they are not exactly
sure what the FDA does. The FDA is a regulatory
agency first and foremost. We are not a research
agency like NIH, and so our mission and what is
written in law is very different from other agencies in
the federal government. We are the oldest consumer
protection agency and we have oversight over a
trillion dollars worth of commerce. On a daily basis
that means about a quarter of every dollar you spend is
something that the FDA is responsible for regulating.
Basically, the FDA receives and reviews research
information 10m companies who want to manufacture
products. We oversee pharmaceuticals, whether they
are prescription or over-the-counter; medical devices,
whether it be a tongue depressor or an implantable
defibrillator the full spectrum. He regulate vaccines
and blood products. We regulate food. Most of the
food in this country is regulated by FDA, but not all.
There are numerous agencies involved with regulating
food, but to make it easy: we do not regulate meat.
He regulate cosmetics. we regulate personal care
products. We regulate veterinary products. Lastly, we

do inspections, inspections at ports. You have heard
a lot about those recently, especially with the recent
peanut butter incident and salmonella in tomatoes
and cilantro. Those inspections at
ports and inspections of research
facilities are conducted by the FDA
should those facilities want to submit
information for approval.
Why is it important that we are even
talking about women in clinical
studies? What does it matter?
According to the Institute of Medicine,
.
.
nine drugs wecre xxithdrawxn from the
market for safety reasons oxver a four
y ear peiriod. Manx of these drugs bad
greater health risks in xvomen and
the top four of tbenx had bealtb risks
specifically in xxomen. In sexveral other products, there
wxere health iisks in both men and xvomen. IHoxwexer,
in tbes~e specific incidenes, it is just wxomen xwho xweie
harmed by the use ot tbe products.
For example, there xwas a particular drug called ITedasnxilI
that xwas taken to an adxvisory comnxittee. These are
large public meetings xxith experts brought in to bold
a public discussion of the data. ITedasmil is basically
used tot wxhat is called atrial fibrillation or atrial fluter.
It is a rapid heart rate condition. IThere xxere similarities
in howx both men's and xxomnen's bodies handled this
drug and the drug xxorked equally xxell in both sexes.
The problem xxas that there xxere twxice as mans female
deaths in these clinical studies. The question xvas then
taken to the adsvisory conxmittee. The committee wxas
asked xxhat it should do given that the drug xxorked
for whbat it xxas intended to be approxved for, but there
xxere qtiestions as to xxhetber it shotild be alloxxed onto
the market. Ihe comxpany proposed specific dosing
tbat xxould be different for omen aixd xxomen, but the
adsvisory committee menxbers unanimxously said, "ixo,
do not approxve this pioduct." As a result, the product
has not been approved by the agency. IThis xxas a huge
bloxx to the company because it takes hundreds ot
millions of dollars to develop a product and the fact
that there are diffeienees betwxeen men and wxomen has
substanxtial economxic imnplicationxs.
In 1977 there xxas a regulation that the FDA put tforwxard
that actually excluded xxomen from clinical studies
and specificallx excluded xwomen ot childbearing

potential from early-phase clinical studies. Ihe problem with that was it
was overly -interpreted to mean women should be excluded from clinical
studies and that all phases of drug development should exclude women.
There are multiple phases of drug development. Although this is not the
purpose of this talk, it suffices to say that some of the earliest studies are
very small - ten, fifteen study participants - and what they basically do is
slowly increase the dose to see if there are any adverse effects. They are
not meant to show whether the drug works. That is the step where women
were supposed to be excluded; not the large, multi-phase-, multi-center-,
multi-country-, 4,000-participant studies. Excluding women right off the
top actually violates some ethical principles. It violates the principle of
autonomy and quashes the ability of a woman to make her own decision as
to whether she wants to assume the risks and the benefits of participating in
such a clinical study. Advocacy groups lobbied hard to have the regulation
changed because it denied women access to some important and innovative
therapies.
What followed in the seventies and the eighties was the 11V epidemic and
the exclusion of much-needed, yet experimental, products for not just a
life-threatening, but also a lethal medical problem. This issued forced a
change in these regulations. In addition, advances in cancers and cancer
therapeutics were also a large reason for advocacy groups to lobby to have
the regulation changed. In 1993, this particular regulation was changed, but
only via a guideline, which is much lower down the threshold of, "is this
something that has to be done?"' versus a more voluntary rule. Evidently
the guideline did reverse the policy and required pharmaceutical companies
to collect information about the participants in their studies. Companies
were also required to analyze the data to look at effectiveness, whether
there were particular adverse consequences, and pharmacokinetics, which
basically gets to the bottom line of dosing.
In the early nineties, the thought was that if we were concerned about
exposure to women of childbearing potential and, hence, the developing
fetus that that concern could be taken care of with the use of appropriate
language in the research protocol. Subsequently, the agency enacted a
regulation in 1998 requiring companies to report in a submission with the
data broken down by age, sex, and race. It does not necessarily say they
have to analyze the studies based on those factors, but that the participants
are spanning the spectrum of the demographics of the population. Another
regulation that the agency has is the clinical hold rule. Ihis regulation
allows the FDA to stop a study if people are excluded from participation
based upon their reproductive capabilities. It is not permissible to exclude
xwomen of childbearing potential or men because they could potentially
impregnate a wxoman and the clinical study could be put on hold as a iesult
of such exelusions.
IThere certainly are challenges to studying xwomen. For one, xxomen are
harder to study. Women ask questions and do not just take things at face
xvalue. IThere are tacilities that do clinical studies tor the industrx xxho do
not wxant to include xxomen because it takes too long to enioll them in
studies because they ask so many questions. W5omen are less hornogenous.
meaning they are more ditticult to analy ze. If the argument is that xxe xxant
to haxve xxomen in the clinical studies. wxe need to understand wxhether xxe
are talking about females in general or boys versus girls. There may not
be that much different between a seven-year-old female and a seven-yearold male. In contrast, there is a huge difference betwxeen a 12 year-old

female and a 12 year-old male. For example, whether females are within
their reproductive potential or where they are in their monthly cycle are
both dramatic physiologic changes that can impact a woman's response
to a medication or contribute to the adverse effects she may experience.
Pregnancy is a whole other matter. Further, there is the issue of whether
someone is perimenopausal or postmenopausal. If you look at this as a
continuum, it is not enough to just say x'women' in clinical studies.
Women are also expensive. The argument around expense is that you may
have to drive up your sample size and enroll more people if you are forced
to enroll a specific number of women. IThere is also the whole issue around
hormiones. WV
omen will continue to menstruate, get pregnant, and become
menopausal. Ihese factors influence the conduct of clinical studies. Another
challenge is the fear of liability. This is what drove the 1977 exclusion
of women, specifically the birth defects associated with thalidomide. This
is the most apparent teratogenic compound that exists. The fear of birth
defects with pharmacologic agents is real and was the basis for exclusion
for a long time. There were also key cases around DES and the Dalkon
Shield that forced companies to be extremely cautious when enrolling
women in subsequent studies.
Why are women not in clinical studies? To exclude women intentionally
is not permissible, but women are often not recruited. IThen there is the
aspect of the large volumes of data. Despite the IT-friendly society that
we live in and the advances in our health information infrastructure. we
are still in the dark ages when it comes to data standards. By this I mean
one data set, one clinical study, cannot necessarily be pooled with another
clinical study because of how certain data is reported. I will give you one
very simple example. The easiest example of a data point is what sex a
person is. In a clinical study. what we want to see is every female and every
male categorized the exact same way with the exact same nomenclature.
So for a male, it always says, "M" and for a female it always says, "F" and
for unknown or not registered it says, "U." TIhat is not the way studies are
conducted. Any symbol can be used. Since you cannot pool intormation
across studies., it is hard to even know the extent of women's participation
in studies.
Katie O'Callaghan * :
Like Kathleen. I am from FDA. She is from the Center for Drug Evaluation
& Research (CDER); I am from the Center for Devices & Radiological
Health (CDRH). My remarks today do not necessarily reflect the official
views of the FDA. Today you have heard about some of the regulatory
background, the difference betxxeen the ouidelines, and xxhat xxe haxve
statutory authority as an agency to do. W5hy is there still a problem wvith the
nmost recent regulation9 Why are xxe still not getting enough information
on wxomen? I am going to talk about the problem, some solutions that are

being discussed, and identify the key players in the game that need to work
together to change the paradigm.
I really like the session title that we were assigned - Diferent on the
Outside. Different on the Jnside? It would seem you would assume that
there are differences rather than assume that there are not. From a scientific
perspective, that affects how you design your studies, how you design your
devices, and even how you treat patients. If you come in with the assumption
that there are difterences, you are going to treat women differently than
men as opposed to treating all patients the same. A lot of the medical field
does not take this approach, especially with cardiovascular disease. Here
are some general examples
not necessarily cardiovascular-specific
that clearly show there is something different on the inside because there
are differences in disease. For osteoporosis, depression, or auto-immune
diseases, there are differences in how things that we do affect our body
and how that interplays with the development of disease; like the impact of
smoking on health.
More women develop and die from heart disease than men. This is
relatively new knowledge in the science and medical fields. Let us start
with some observations. Look at what we know about the outcomes of
heart disease: more women die of it, women are more likely to die from
a heart attack, more women are likely to die from heart failure and after
having a heart attack, more women are likely to have another heart attack.
Even when women are treated, there may be differences in how well the
treatment works in terms of effectiveness or the types of side effects or
adverse events. Why is this? Specialists say it is because the difference with
female patients is that they are older when they develop heart disease and
they have more co-morbidities like diabetes or obesity. Why are women
being diagnosed so late? L et us take a look at access. Some relatively recent
studies have uncovered disparities in health care delivery for men and
women with heart disease. Women are less likely to get an EKG, which is
a standard diagnostic test for heart disease. Other diagnostic tests are often
less accurate in detecting heart disease in women. WXomen are less likely
to be referred to a heart disease specialist. When women do get treatment,
they are less likely to get the right treatment, such as clot-busting drugs or
catheterization procedures.
Why are women not getting the right treatment ? As it turns out.v,
we are

still in the learning phases, from a scientific perspective, when it comes to
the biology. There is a lot being uncovered, but we are still learning about
the ways in which women and men are different, biologically speaking, in
diseases that affect both. For things like breast cancer or pregnancy-related
conmplications swe hasve a relatisvely good understanding about boy vsomen
and men are different. But for things like heart disease, vse hasve just been
treating nmales and females the sanse whlen, in factL there may be maletypical lheart disease swith some sariatioin and fensale-typical heart disease
vsith sonse svariation.
WXhat about solutions? Let us start wvith educating vsomen; patient
awvarencss. The red dress campaign is one example. There is also the 'Go
Red for \Xumen' campaign. There is a lut uf usverlap and cullaburatiun
bctvveen the nmedical professional societies, NIH. patient advocacy groups,
and there is outreach to female patients who have heart disease. Slowly but
surely there has been a measurable increase in how much the public knows
about heart disease in women.

As a result of education programs, more female patients know they are at
risk for heart disease. What about the referral bias and the delivery disparity
issues that we were talking about earlier? We do need to educate providers,
but if there is a referral bias issue we cannot just talk to the cardiologists;
we have got to go a step back. We need to talk to the primary care doctors,
the ER doctors, or the 01BGYNs swhich, for many women, is their primary
care physician. We need to go to the medical schools. IThe Association of
American Medical Colleges has actually been looking at integrating more
gender-specific teaching into their curriculum. A medical professional
society has put out practice guidelines and there have been a few that have
come out for treating and diagnosing women with heart disease.
TFhe next issue is what to put in those guidelines. Ilow should we be
diagnosing and treating women with heart disease? We need to talk about
research. What do we know about the biological reasons for sex differences,
both in the healthy female versus the healthy male and then in men and
women with heart disease, and then how they respond to the treatment? We
need to analyze the trial data that we have in the drug, device, and treatment
trials and look for and report any differences. When we try to do that, the
statisticians say. "there are not enough women." The signals are still within
the margin of error. WX
e need to get more women involved. How do we
do that? Patient awareness. At that point we have completed the circle. I
am trying to paint a picture of how there are many components of this
system that are all operating under the current paradigm. Ihe regulation
and policy issue is one aspect of it, but really it is going to require all of
these pieces consing together. Who is responsible'? In my opinion, all of the
above: patients, primary care and specialist medical providers, the research
industry who are designing the medical devices and drugs, the FDA, NIlI,
and the pay-ors.
Our panel is also talking about rethinking nedical models and clinical
trials. Ihe FDA is trying to change the paradigm by putting out a guideline
for trials and marketing applications for medical devices. W"e are talking
with the industry about enrollment targets to include more women in trials,
evaluating data to identify what information should be released to the public
and what necessitates further study, identifying barriers to women enrolling
in studies, assessing at what point in the study are they dropping out,
figuring out ways to minimize that, and studying other systematic changes.
We need more data about sex-based differences and this will come about
with an FDA-industn partnership, through the NIH's work with academia
to conduct studies, incentives from CMS and the other insurance providers,
and practice guidelines from medical professional societies.
Rebecca Wolf:
I vsill be discussiing a two-part article about personalized inedicine wshich
I co-authored swiths Professor Corrine Parsver, sexveral other WXCI students,

and health law practitioners. I will be touching on a few of the pertinent
health law issues addressed in these publications. I will be explaining the
new technology of pharmacogenomics (juxtaposed against traditional
model of one-size-fits-all medicine) which was made possible, in part, by
the Human Genome Project that was completed in 2003. 1 will be discussing
the benefits and concerns associated .with personalized medicine, namely
the exacerbation of gender inequities in clinical trials and concerns about
genetic-based discrimination. In that vein, I will be describing some of the
legal provisions which can protect individuals from genetic discrimination.
Finally, I will conclude that pharmacogenomics is a promising new field
of medical research which has the potential to revolutionize the field
of medicine. lHowever, it is important to consider and address gender
inequities and clinical trials. In addition, potential genetic discrimination
means that there is a need for scrupulous legal protection.
One-size-fits-all medicine is when the general population receives
essentially the same treatment for a particular disease. The only tailoring
that occurs is for adults, children, and the elderly. One-size-fits-all medicine
does not provide additional information about how an individual patient
will react to a particular type of treatment or what type of dosage would be
beneficial given that patient's rate of drug metabolism. Two benefits of onesize-fits-all medicine are as follows: first, one-size-fits-all medicine is less
costly in the short term than tailoring treatments for each individual patient;
second. standardized treatment simplifies interventions.
lowever, there are many concerns associated with one-size-fits-all
medicine. First, individual differences and drug metabolism can result in
ineffective treatment or a drug overdose., in some patients. Second, ignoring
genetic differences can result in serious side effects. In fact, only one-third
of all drugs act as expected when prescribed. For instance, in the treatment
of asthma, the same drug can provide relief for one patient and have serious
side effects for another. In a heterogeneous population, such as in the
United States, there will be less predictability of reaction to treatment due
to a diverse gene pool.
Pharrmacogenomics, or personalized medicine, is an alternative to one-sizetits-all medicine. It was made possible, in part, by the IHuman Genome
Project. T-he luman Genome Proiect was an effort to decode the sequence
of DNA and map the entire human genome. The luman Genome Project
may ultimately give medical providers information about an individual's
predisposition to developing a particular disease or the way in which an
individual will react to a certain type of medical treatment. Personalized
medicine is the marriage of oenomic technologies and pharmaceuticals.
The primary purpose of personalized Inedicine is to indiv idualize medical
treatment for each patient's DNKA.
Unlike one-size-fits-all medicine, personalized medicine is much more
likely to be beneficial and safe for a particular patient because a phy sician
preseiibes a particular drug and dosage based upon the indixidual's
genotxype. Theire are sexveiral benefits of personalized medicine. First, there
is a potential for more effectixve treatments for each indiv idual. Second,
plhysicins may intcrvene. at ani earlier stage of a disase. or even before
a disease manifests based upon knoxxledge of a patient's predispositions.
Third, personalized medicine may help researchers identify disease targets,
speed clinical trials, and advance treatments for specific populations.
Itowever, as with any new technology, there are also associated concerns.

Two concerns that I will be discussing are that personalized medicine
could exacerbate gender inequities in medicine and that individuals will
experience discrimination based upon their genetic information.
There is a historical lack of inclusion of women in medical research. Until
the late 1980s, women were excluded from participating in clinical trials
through explicit policies, practices, and severe neglect. In 1993, the NIH
Revitalization Act required the inclusion of women in clinical studies, as
well as the analysis of research results by gender. Noxx, more than fifteen
years later, despite the NIl Revitalization Act, women remain excluded
from clinical trials. As you can imagine, if women are excluded from
clinical trials related to personalized medicine, then there will be a paucity
of information about how to treat women on an individual basis.
In addition to exacerbating gender inequities, there is a concern that
individuals will experience discrimination based upon their genetic
infonmation. Genetic discrimination occurs when people are treated
unfairly because of differences in their DNA that increase their chances of
getting a certain disease. For example, a health insurer might refuse to give
coverage to a wxoman who has a genetic predisposition for breast cancer.
Employers also could use -DNA inflormation to decide whether to hire or
tire workers. T-his is particularly troubling in the current economic climate
in which companies are trying to save money. To employers, it might be
more cost-effective to employ someone who is not predisposed to a costly
disease.
There are several existing legal protections against genetic discrimination.
Title VII of the CivilI Rights Act of I964 prohibits all private employers with
tifteen or more workers; labor organizations. employment agencies and
federal, state and municipal government employers from discrimination on
the basis of race, color, religion, sex or national origin. The statute does
not specifically address discrimination based upon genetic information but
Title VII may protect against discrimination on the basis of an individual's
genetic makeup if that discrimination disproportionately impacts
individuals belonging to a protected class. The Americans with Disabilities
Act (ADA) prohibits discrimination in employment, public services, public
accommodations and communication against individuals with disabilities.
In March 1995, the Equal Employment Opportunities Commission issued
an interpretation of the ADA that states: "[e]ntities that discriminate on
the basis of genetic predisposition are regarding the individuals as having
impairments and such individuals are covered by the ADA." IHowever,
because interpretation has not yet been tested in the legal arena, it remains
an interpretative policy guideline.
The Health Insurance Portability and Accountability Act, or HIPAA,
ensures that iindixviduals xvio chainge health coxverage are not denied or
restricted in employmnent-related coxverage on the basis ot a preexisting
coindition. IHIPAA xxas die first federal laxw to address die use of genetic
informiation in the health insurance context. It prohibits group health plans
and group health insuiers from excluded indiv iduals from coxverage on
the basis ot genetic intormation unless there is an actual diagnosis of die
conditioni melted to the genetic information. In 2000, President (lnona
signed an executixve ordei prohibiting exvery federal department and agency
from using genetic information in any hiring or promotion action.
Finally, and most recently, the Genetic Information Nondiscrimination
Act (GINA) oh 2008 prohibits the improper use of genetic information in

health insurance and employment. The Act prohibits group health plans and
health insurers from denying coverage to a healthy individual or charging
that person higher premiums based solely on a genetic predisposition
to developing a disease in the future. It also bars employers from using
individuals' genetic information when making hiring, firing, and job
placement or promotion decisions.
In conclusion, pharmacogenomics is a promising new field of research
which has the potential to revolutionize medicine as we know it. However,
it is important to consider and address gender inequities in clinical trials.
In addition, potential discrimination based upon genetic information means
that there is a need for scrupulous legal protections.
Audience

Question:

Is there anything happening now to address the refusal to include women
in clinical trials? Will it be just the same kind of situation but with a new
dynamic with pharmacogenomics or, in fact, will we resolve it? There
seems to be a real opportunity for personalized medicine to exclude half of
the country. Is something being done?
Kathleen Uhl:
It is interesting that you bring that question up because there are certainly
genomic databases that exist and it is not that surprising that some of the
data does not include information about sex. Alarge database of intormation
on multiple patients with no information on their sex is not going to answer
any of the questions that you hasve raised. It comes back to the issue of data
standards. What are the standards that need to be collected for every patient,
not just in research but at every clinical encounter? How do we develop a
systematized manner of collecting health information so that a patient's
sex is collected every time? That question is actually addressed through
the health IT aspect of the stimulus package. Health IT is important, not

just for the patients' electronic medical record with his or her practitioner,
but also the accessibility of that record. Someone entering medical data in
Washington, D.C. or Portland, Oregon will complete all the same fields for
every encounter. IThat is still in the works. Ihere are certainly systems that
use electronic health records but yet there is no universal electronic health
record.
Katie O'Callaghan:
Health IT has been getting a lot of attention as part of an overall health
reform. It has potential to be part of the solution, because when everything is
electronic, it may be easier to standardize data or at least access data. Often,
for the data vse receisve at the agency 1ev el, it 55ould be really burdensome
to go hack to the actual patient-lev el data and determine wvhether the
patient wsas male or female. With electronic records it becomnes mueh more
accessible. There's also a Heart Aet for Wonmen vshich passed last year in
the IHouse and did not make it through the Senate, but is being reintroduced.
The Agency for H ealthcare Research and Quality, vshich creates dispairities
reports, vsould be charged svith doing svomen-specific reports by utilizing
information tiom various databases, nationwside information iesouices. and
certainly any thing that vsouki become available svia a health IT initiative.

Kathleen Uhl:
I want to comment about the use of the terminology 'excluded' versus
'not included', because they mean two different things. Women can be
intentionally excluded from participation in studies, like they were in the
1970s. They were not allowed to participate in studies: totally excluded. In
today's situation, and using cardiovascular health as an example, women are
not included in the studies to the same extent that men are. They certainly
are included. There are some great meta-analyses in medical literature that
assess women's participation in large. multicenter cardiovascular studies
and for drugs and devices. Women represent twenty to thirty percent of
participants. Women are not expressly excluded but if the enrollment
criteria states that participants must be under age sixty five, fewer women
will be included, because they tend to develop heart disease at an older age
than men.
It is a subtlety to say that, but there are people who would take exception
to anyone saying women are excluded from studies because there is policy,
regulation, and lays that prohibits the exclusion of women from studies.
Katie O'Callaghan:
The other piece, as far as the genomics and personalized medicine go, is
that there have been an increasing number of reports fromn the basic science
research field finding that the receptor associated with this marker for heart
disease is much more prevalent in women than in men. I think the more we
start to learn about the genetic predisposition to disease, the more that may
come into play.
Audience

Question:

Last February, the Supreme Court ruled on a case that gave a huge amount
of deferential authority to the FDA. Specifically, if something is reviewed
and approved by the FDA then. even if it is defective and hurts somebody,
they cannot bring a lawsuit. Now. I just wanted to know what your opinion
of that is because what happens if there is another Dalkon Shield or DES
case? Somebody who is injured by that cannot bring a lawsuit. I want to
know what their remedy is. Ihey cannot go to the court, they cannot get any
relief or remedy for that or prevent this from happening again, and I wanted
to know what your opinions were on that decision.
Katie O'Callaghan:
I do not know all the legal specifics of the court case from reading the news
reports. I believe that the decision, in regards to preemption, is about not
suing the company if the dev ice or ding wsas used exactly as the label swas
vsrrtten by the EDAf foi the approved use in patients. The issue vsith FDA
trials and off-label marketing or usage of treatmenlt is that the studies that
EDA rieceives. iesiesvs, and evaluates the treatmnent on are svery specific
and, oftentimes phy sicians use themn in areas that are not studied. In those
cases, I do not think that preemption vsould rule out medical malpractice
suits. So if you are harmed as a result of off-label usage of a desvice, drug,
or a biologic by your phy sician, Inedical malpractice is still not ruled out
by premption.

Moderator:
Dr. Uhl, vou talked about the differences among women and how that
creates a difficulty in women being part of clinical trials. I was wondering
if you had any thoughts about how to address those differences to make it
possible for women to be part of those clinical trials in a real, concrete way.
Kathleen U!hl:
Well, the reason I discussed that was two-fold: one, to let people see some
of the barriers and two, to emphasize the heterogeneity of the female
population. That is more the food-for-thought part of the talk. It is what we
need to think about it if the game plan is to increase participation of women
in studies and specifically, find out how applicable the data is to the entire
female population? So, if we are just studying women who are under tortyfive in a particular area, but there are women in their seventies or eighties
that will be taking or using this same medical product, how applicable is
that data 9 I do not have the answer to that, but I think that the way to
answer those questions is probably not in the context of pharmaceutical
or device-sponsored studies because, if that is the expectation, we will not
see any new medical products on the market. If the expectation is, as Katie
alluded to, some of these large claims databases that AHRQ, theAgency for
Healthcare Research and Quality, or CMS have access to, then we will be
able to better address the effects from medical product usex,
whether they
are efficacy or safety, in different populations of women.
I also put it there to show that there will always be excuses as to why we
do not study more women. If you want to counter them you have to know
what they are in the first place and why people feel that way. Then you can
go to the next step and say, "how do we improve the recruitment of women
in clinical studies?" That is an entirely different focus that requires the next
question to be "how do you promote recruitment and retention of women
in clinical studies?"
Katie O'Callaghan:
As far as cardiovascular trials, the agency had a public workshop - two,
actually; one in June and one in December - specifically looking at that.
We got together a group of physicians via professional societies, patient
advocacy groups, and several of the agencies under HHS: FDA, NIH,
CMS, and AHRQ. When you look at anything, be it heart disease or
prevention or any type of access to the healthcare system, there are a lot of
disparities in women and men accessing healthcare. Then there are separate
disease-specific or product-area-specific issues. For example, with heart
diseasc, one thino that I learned fronm a think tank rclates to body inmagc and
cultural issues. An ER doctor had mcntioncd that one of the reasons xxhy he
thought wxomen might be less likely to get the IEKG is because in a croxxded
ER, xxhen you do not base a room axailable. a guy xxho has chest pain is
conmfortable xwith tearing his shirt off and strapping on all the electrodes for
the EKG. If a xvoman has mild chest pain and is short of breath, she may
not xvant to tear her shirt off. She is still fully cogniiant. She is not talling
on the ground and she does not necessarily knoxx it is a heart attack. She is
probably goig to wxait fur the ruom. Thcrc ar disease-specific issues but it

is really very multifaceted and it is going to take collaboration from all the
stakeholders to figure out what is needed for each specific area.
Kathleen Uhl:
The heterogeneous population of women has didferent requirements if you
want them in clinical studies. IFor example, if you want to recruit women
into a clinical study who are twenty to torty years old and have kids., unique
issues arise. llow are you going to get her into your clinical study? You
have to provide childcare at the site of the clinical study. You probably
have to provide transportation. For the aging female population, as shown
by information presented earlier today talking about salary and income,
older women are living below the poverty line. If you want to enroll older
women, they are more likely to have a need for bus fare or cab fare to get
to the site of the study. There is not a cookie-cutter approach to participant
enrollment, yet this is the paradigm that has been followed in the research
commuity.
Audience

Question:

My question is about issues that are only related to women; namely,
reproductive health. What is going on with the trials there'? I know there
were a lot of issues when birth control first came out and there are some
moral/ethical dilemmas with those trials.
Kathleen Uhl:
It depends in which area you are referring. For example, there are a lot of
studies ongoing for osteoporosis. Since there is certainly a great market
for contraception, companies are still creating new contraceptives, whether
they are drugs or devices or drug/device combinations.
The area of pregnancy is where there is really a dearth of information
because of the liability aspect. WX
e know pregnant women get sick. We know
pregnant women need medical treatment. Whether they need diagnostic
tests, they need treatment with medication or treatment with medical
devices. The community of clinicians and the developers of these products
are scared to death to touch pregnancy because of liability. There are very
few products under development for use during pregnancy. There may be
more in the medical device area because of use in labor and delivery, but
when it comes to medication, there is a dearth of studies to collect that. Ve
know women take medication when pregnant. Ihere have actually been
numerous workshops to discuss this and ask questions like "is it ethical
to study the use of medical products in pregnancy?" The counter is, it is
unethical not to. If the standard of care is to use this particular drug for a
patient xwith asthma xxhen pregnant, then hoxx is it unethical to studx the
outcomes in the xxoman or in her dexveloping fetus trom that exposure9
Though the ethics around it are substantial, the medical liability pait is esen
larger. I think thec ofhei part around pregnancy is that it is a limited-term
medical condition xxhere the end result. in the maj orifx of circuinstanccs,
is a hcalfhy baby. Thc issues around pregnancy tend not to bc embraced as
much by the xxomen's health adxvocacy community.

